Find disease awareness content and relevant supporting materials
Release of positive results for denosumab biosimilar integrated phase I/III clinical trial
Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab
3D modelling of hip DXA scans in postmenopausal women with osteoporosis reveals superior improvements in bone density of romosozumab versus controls
UCB and Amgen, presented abstracts of three post-hoc analyses focusing on 3D modelling techniques that highlight significant cortical and trabecular bone improvements in patients treated with romosozumab.